The global oncology/cancer drugs market was valued at $97,401 million in 2017, and is estimated to reach at $176,509 million by 2025, registering a CAGR of 7.6% from 2018 to 2025

Wednesday, April 3, 2019 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 2, 2019 /PRNewswire/ -- Oncology/Cancer Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Read the full report: https://www.reportlinker.com/p05757855/?utm_source=PRN Oncology Drugs Market Overview:The global oncology/cancer drugs market was valued at $97,401 million in 2017, and is estimated to reach
at $176,509 million by 2025, registering a CAGR of 7.6% from 2018 to 2025.Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option to treat various cancer types, especially blood cancer (leukemia). Rise in incidence of various cancer conditions, increase in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide are the key factors driving the growth of the global oncology/cancer drugs market. Furthermore, rise in cancer awareness and availability of cancer drugs are expected to boost the market growth.However, high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future. The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).Key Benefits for Oncology Drugs Market:The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities. A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.Oncology Drugs Key Market Segments:By Drug Class Type ChemotherapyTargeted TherapyImmunotherapy (Biologic Therapy)Hormonal TherapyBy Indication Lung CancerStomach CancerColorectal CancerBreast CancerProstate CancerLiver CancerEsophagus CancerCervical CancerKidney CancerBladder CancerOther CancersBy RegionNorth AmericaU.S.CanadaMexicoEuropeGermanyFranceUKItalySpainRest of EuropeAsia-PacificIndiaChinaJapanAustraliaSouth KoreaRest of Asia-PacificLAMEABrazilSouth AfricaSaudi ArabiaRest of LAMEAList of Key Players Profiled in the ReportAbbVie Inc.Astellas Pharma Inc.AstraZeneca PLCBristol-Myers Squibb CompanyCelgene CorporationF. Hoffmann-La Roche Ltd.Johnson & Johnson (Janssen Global Services, LLC,)Merck & Co., Inc.Novartis AGPfizer Inc.LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)SanofiAmgen Inc.Bayer AGExelixis, Inc.Read the full report: https://www.reportlinker.com/p05757855/?utm_source=PRN About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-global-oncologycancer-drugs-market-was-valued-at-97-401-million-in-2017--and-is-estimated-to-reach-at-176-509-million-by-2025--registering-a-cagr-of-7-6-from-2018-to-2025--300823104.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store